Competitive pressures in the US have led Hikma to once again slash its Generics guidance for 2022, cutting its full-year sales expectations for the unit to $650m-$675m, with a core operating margin expected to come in at 15%-16%, in the face of “persistent challenges” in the US generics market.
Challenges highlighted by Brian Hoffman, president of the Generics division, included defending some of the firm’s top products in the face of increased competition – after fresh rivals to Advair Diskus (fluticasone/salmeterol) and Vascepa (icosapent ethyl) recently entered the market (Also see "Hikma Still Sees Value In Generic
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?